Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Regulatory
  3. /MHRA

Regulatory

MHRA(39)

Track how regulatory decisions alter competitive positioning, launch timelines, and investor expectations across therapeutic areas.

39 signals

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ScoreIntelligence Record
8.0

REGULATORY

Aficamten Approved by MHRA and Recommended by NICE for Heart Condition

Aficamten has received approval from the MHRA and a recommendation from NICE for use in patients with a serious heart condition.

Aficamten·July 31, 2026
7.0

REGULATORY

MHRA Issues Guidance on Safe Use of GLP-1 Weight Loss Medicines

The MHRA emphasizes the importance of safe usage of GLP-1 medicines amid rising demand for weight-loss solutions.

MHRA·July 25, 2026
8.0

REGULATORY

Domperidone Updated with New Contraindication for Phaeochromocytoma Patients

Domperidone products now include a contraindication for patients with confirmed or suspected phaeochromocytoma due to severe hypertension risk.

Domperidone·July 22, 2026
7.0

REGULATORY

MHRA Approves First Lower-Carbon Beclometasone Inhalers for Asthma

The MHRA has approved the world's first lower-carbon beclometasone inhalers, utilizing a next-generation propellant.

MHRA·July 22, 2026
7.0

REGULATORY

Manufacturing Issue with Xaggitin XL Tablets Reported by Martindale Pharma

A manufacturing defect has been reported for Xaggitin XL Prolonged-release Tablets, affecting tablet counts in multiple batches.

Macarthys Laboratories Ltd·Manufacturing·July 21, 2026
7.0

REGULATORY

Teva Reports Labelling Error for Ponlimsi (Denosumab) 60mg Injection

Teva UK Limited has identified a labelling error on the Ponlimsi (Denosumab) carton, incorrectly stating 'For application to the skin'.

Ponlimsi (Denosumab)·July 19, 2026
8.0

REGULATORY

Resmetirom (Rezdiffra) Approved for MASH Treatment in Adults

Resmetirom (Rezdiffra) has been authorized for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults.

Resmetirom·July 19, 2026
8.0

REGULATORY

MHRA Strengthens Warnings for Botulinum Toxin Type A Products Due to Botulism Cases

The MHRA has issued updated safety warnings for botulinum toxin type A products due to rare cases of botulism.

MHRA·July 16, 2026
8.0

REGULATORY

Updated Warnings on Botulinum Toxin Type A Products Due to Iatrogenic Botulism Risk

Iatrogenic botulism cases have been reported following the use of botulinum toxin type A products, indicating a risk of toxin effects extending beyond treatment areas.

Updated·July 16, 2026
8.0

REGULATORY

Crescent Pharma recalls Ramipril 2.5mg due to packaging error

Crescent Pharma Limited is recalling Ramipril 2.5mg capsules due to a packaging error that may lead to patients receiving the incorrect dosage.

Crescent Pharma Limited·Crescent·July 13, 2026
8.0

REGULATORY

Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation

The Allurion Gastric Balloon may cause serious complications, including gastric outlet obstruction, small bowel obstruction, and gastric perforation.

Allurion·July 13, 2026
8.0

REGULATORY

Project Orbis Aims to Accelerate Cancer Drug Approvals

Project Orbis is designed to expedite the review and approval process for promising cancer therapies.

Project·July 11, 2026
6.0

REGULATORY

Bristol Laboratories recalls Phenoxymethylpenicillin due to labeling issues

Bristol Laboratories Limited is recalling batch 7124002 of Phenoxymethylpenicillin 250 mg/5 ml Oral Solution due to labeling issues.

Bristol Laboratories Limited·Phenoxymethylpenicillin·July 10, 2026
7.0

REGULATORY

MHRA Reviews Safety of Five Plasma-Derived Products for vCJD Risk

The MHRA has completed a review of five plasma-derived medicinal products regarding their safety related to vCJD risk.

MHRA·July 10, 2026
8.0

REGULATORY

MHRA Approves UK Plasma Donations for Key Medicinal Products

The MHRA has approved the use of UK-donor plasma for five high-priority plasma-derived medicinal products.

MHRA·July 10, 2026
8.0

REGULATORY

Nerandomilast (Jascayd) Approved for Idiopathic and Progressive Pulmonary Fibrosis

Nerandomilast has received approval from the MHRA for the treatment of adult patients with idiopathic and progressive pulmonary fibrosis.

Nerandomilast·July 9, 2026
8.0

REGULATORY

Risk of Severe Harm from Incorrect Blood Transfusion Administration Sets

Using an IV infusion giving set instead of a blood transfusion giving set poses a risk of serious harm to patients.

Severe Harm·July 9, 2026
8.0

REGULATORY

Semaglutide (Wegovy) approved for metabolic-associated steatohepatitis treatment

Semaglutide injection has received approval for the treatment of metabolic-associated steatohepatitis in adults with moderate-to-advanced liver fibrosis.

Wegovy·July 4, 2026
6.0

REGULATORY

Milpharm Limited Issues Class 4 Medicines Defect Notification for Loperamide Hydrochloride

A discrepancy has been identified in the Patient Information Leaflet for Loperamide hydrochloride 2 mg Orodispersible Tablets.

Milpharm·July 3, 2026
8.0

REGULATORY

MHRA Approves Gemcitabine Delivery System for High-Risk Bladder Cancer

The MHRA has authorized a new intravesical delivery system for gemcitabine aimed at adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer.

MHRA·July 2, 2026
6.0

REGULATORY

Flamingo Pharma recalls Flucloxacillin Capsules due to incorrect patient information leaflet

Flamingo Pharma UK Ltd has recalled certain packs of Flucloxacillin Capsules BP 500mg due to containing the incorrect patient information leaflet for Amoxicillin.

Flamingo Pharma UK Ltd·Flamingo·July 2, 2026
6.0

REGULATORY

Brancaster Pharma Issues Class 4 Medicines Defect Notification for Benzylpenicillin

Brancaster Pharma Limited reported that certain batches of Benzylpenicillin benzathine were released with an outdated Patient Information Leaflet.

Brancaster Pharma Limited·Brancaster·June 30, 2026
6.0

REGULATORY

Defect Notification for Hiprex 1g Tablets Due to Braille Embossing Error

A Class 4 Medicines Defect Notification has been issued for Hiprex 1g tablets due to an error in Braille embossing on packaging.

Doncaster Pharma Limited·Defect·June 29, 2026
7.0

REGULATORY

Sandoz Issues Class 4 Medicines Defect Notification for Apixaban Tablets

Sandoz Ltd. reported that the Patient Information Leaflet for certain batches of Apixaban tablets lacks up-to-date information.

Sandoz·Apixaban·June 28, 2026
7.0

REGULATORY

Quadrant Pharmaceuticals Issues Class 4 Medicines Defect Notification for Vesomni Tablets

Quadrant Pharmaceuticals has reported Class 4 Medicines Defect due to incorrect barcode/GTIN on Vesomni tablets.

Quadrant Pharmaceuticals·Vesomni·June 28, 2026

Showing 1–25 of 39 records

Page 1 of 2